Loading…
Company reports significant mobilization of CD34+ cells in trial participants.
Exicure, Inc. announced on 2025-12-08 Exicure announced positive topline Phase 2 data for burixafor in multiple myeloma.
17 of 19 participants. 14 of 16 participants. 12 of 14 participants. The announcement cited 90%, 89.5%, 13 days, 17.5 days, 84.2%, 87.5%, 85.7%, and 2 × 10⁶ CD34+ cells/kg.
Exicure, Inc. Common Stock has a free float of 2,384,000 shares and 6,373,900 shares outstanding.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.